Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health is expected to experience continued growth in its three reportable segments due to its strong competitive positioning, potential for cross-selling, and investments in emission control systems. Additionally, the company is focusing on customer education and improving connectivity for further growth opportunities. With a strong emphasis on generating free cash flow and a global presence in its subsidiaries, Sotera is poised for continued success in its industry.

Bears say

Sotera Health is facing challenges with legal issues and underperformance, but the company has taken steps to address these issues and has potential for growth with new regulations and expansion into the pharmaceutical industry. The acquisition of Nelson Labs has also provided the company with a strong market opportunity and credibility, giving it a sustainable scale advantage. Challenges may arise in obtaining necessary licenses and renewing leases, but Sotera's strong financial profile and integrated offerings position it well for long-term partnerships and cross-selling opportunities.

Sotera Health (SHC) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 7 analysts, Sotera Health (SHC) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.